Results 71 to 80 of about 2,763 (183)

The pharmacology of gepants in migraine: A scoping review on mechanisms, clinical applications, and combination strategies

Headache: The Journal of Head and Face Pain, Volume 66, Issue 7, Page 1628-1643, July/August 2026.
Abstract Background Calcitonin gene‐related peptide (CGRP) is a key mediator in migraine pathophysiology, and the development of gepants, novel CGRP receptor antagonists, has expanded therapeutic options for both acute and preventive treatment. This scoping review aims to synthesize current evidence on the pharmacology, clinical applications, safety ...
Luigi Francesco Iannone, Marcello Silvestro, Antonio Munafò, Marina Romozzi, Pierangelo Geppetti, Antonio Russo   +5 more
wiley   +1 more source

Evaluation of the effect of erenumab on migraine‐specific questionnaire in patients with chronic and episodic migraine

CPT: Pharmacometrics & Systems Pharmacology, 2023
Erenumab is a fully human anti‐canonical calcitonin gene‐related peptide receptor monoclonal antibody approved for migraine prevention. The Migraine‐Specific Quality‐of‐Life Questionnaire (MSQ) is a 14‐item patient‐reported outcome instrument that ...
Po‐Wei Chen, Mats O. Karlsson, Sebastian Ueckert, Ari Pritchard‐Bell, Cheng‐Pang Hsu, Sandeep Dutta, Malidi Ahamadi   +6 more
doaj   +1 more source

GPCRs in CAR‐T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy

Advanced Science, Volume 13, Issue 35, 24 June 2026.
Chimeric antigen receptor T cell therapy faces dual challenges of target scarcity and an immunosuppressive microenvironment in solid tumors. This review highlights how G protein‐coupled receptors can serve as both novel targets to expand the therapeutic scope and functional modules to enhance CAR‐T cell efficacy.
Zhuoqun Liu, Yuchen Xiao, Yamin Zhao, Lihe Dai, David J.H. Shih, Shikang Liang, Honglei Tian, Liu Liu, Feng Tian, Bing Liu, Lei Chang, Chao Zhang   +11 more
wiley   +1 more source

Implications of therapy interruption on monthly migraine days and modified migraine disability assessment in patients treated with erenumab for chronic and episodic migraine: SQUARE study interim results. [PDF]

BACKGROUND There are limited real-world data in Switzerland examining the impact of erenumab, a fully human IgG2 monoclonal antibody targeting the calcitonin gene-related peptide (CGRP) receptor, on migraine-related quality of life.
Meyer, Ina, Kamm, Christian P, Agosti, Reto, Gantenbein, Andreas R, Bonvin, Christophe, Pohl, H., Ryvlin, P., Kulartz-Schank, Monika, Bonvin, C., Arzt, Michael E, Gantenbein, A.R., Meyer, I., Zecca, C., Kamm, C.P., Agosti, R., Rudolph, Nicole, Merki-Feld, G.S., Merki-Feld, Gabriele Susanne, Schankin, Christoph J, Zieglgänsberger, Dominik, Zecca, Chiara, Schäfer, E., Arzt, M.E., Pohl, Heiko, Rudolph, N., Ryvlin, Philippe, Kulartz-Schank, M., Zieglgänsberger, D., Schankin, C.J., Schäfer, Elisabeth   +29 more
core   +2 more sources

ESTELA‐Study: Long‐Term Effectiveness and Safety of Anti‐Calcitonin Gene‐Related Peptide Monoclonal Antibodies in Real‐World Clinical Practice

Brain and Behavior, Volume 16, Issue 6, June 2026.
ABSTRACT Background Anti‐CGRP antibodies are effective and safe in real‐world migraine management, but guidelines recommend discontinuation after 12–18 months due to limited long‐term data and remaining uncertainties regarding optimal treatment duration and sustained safety, highlighting the need for large‐scale long‐term real‐world evidence.
Alba Somovilla, Iris Fernández‐Lázaro, Josué Pagán, Daniel Saiz, Javier Díaz‐De‐Terán, Leonardo Portocarrero Sánchez, Germán Latorre, Carlos Calle De Miguel, Nuria González‐García, María‐Luz Cuadrado, Jesús Porta‐Etessam, Javier Casas‐Limón, David Garcia‐Azorin, Ángel Guerrero‐Peral, Yésica González‐Osorio, Alicia Gonzalez‐Martinez, Guillermo Martín Ávila, Rodrigo Terrero Carpio, Jaime Rodríguez‐Vico, Alex Jaimes, Andrea Gómez García, Cristina Trevino‐Peinado, Margarita Sanchez‐Del‐Rio, Alberto Lozano Ros, Antonio Sánchez‐Soblechero, Sarai Urtiaga Valle, Marta González‐Salaices, Elena Riva, Ana Gago‐Veiga   +28 more
wiley   +1 more source

Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study. [PDF]

, 2019
OBJECTIVE: To determine the effect of erenumab, a human monoclonal antibody targeting the calcitonin gene-related peptide receptor, on health-related quality of life (HRQoL), headache impact, and disability in patients with chronic migraine (CM). METHODS:
Nilsen, Jon, Leonardi, Dean K., Mikol, Daniel D., Reuter, Uwe, Desai, Pooja, Lipton, Richard B., Silberstein, Stephen, Tepper, Stewart J., Stewart, Walter F., Cheng, Sunfa, Lenz, Robert   +10 more
core   +1 more source

Did the French pregnancy pictogram change antiseizure medication use during pregnancy?

Epilepsia, Volume 67, Issue 6, Page 2864-2874, June 2026.
Abstract Objective The aim of this study was to assess the impact of introducing a pregnancy pictogram on medication packaging on the prescription and dispensation of antiseizure medications and on the maternal and neonatal outcomes for women exposed to these medications.
Mélanie Araujo, Christine Damase‐Michel, Marie Denuelle, Sébastien Boulogne, Laurane Delteil, Monica Saucedo, Catherine Deneux‐Tharaux, Isabelle Lacroix   +7 more
wiley   +1 more source

Erenumab and the migraine brain - an event-related, randomized, double-blind, placebo-controlled study

, 2020
Possible central effects of the monoclonal CGRP-antibody (CGRP-mAb) erenumab are not yet elucidated. This event-related, randomized, double-blind, placebo-controlled study aims to discover functional changes in pain processing after the administration of
Hauke Basedau, Prof. Dr. Arne May, Christian Ziegeler, Kuan-Po Peng   +3 more
core   +1 more source

Is erenumab an efficient alternative for the prevention of episodic and chronic migraine in Spain? Results of a cost-effectiveness analysis

The Journal of Headache and Pain
Background The reimbursement of erenumab in Spain and other European countries is currently restricted because of the cost of this novel therapy to patients with migraine who have experienced previous failures to traditional preventive treatments ...
Patricia Pozo-Rosich, José Luis Poveda, Carlos Crespo, María Martínez, José Manuel Rodríguez, Pablo Irimia   +5 more
doaj   +1 more source

Headache psychiatry: A structured narrative review and integrative framework

Psychiatry and Clinical Neurosciences Reports, Volume 5, Issue 2, June 2026.
Headache disorders are among the most prevalent and disabling neurological conditions worldwide, yet their psychiatric comorbidities remain systematically underrecognized in clinical practice. This narrative review introduces Psychocephalology—a biopsychosocial framework conceptualizing headache through five interacting domains: neurobiology, pain ...
Kyohei Otani
wiley   +1 more source